Mauritius Entity Sells Rs 289 Crore Stake in Emcure Pharmaceuticals to Norges Bank Through Block Deal.
On Wednesday, Emcure Pharmaceuticals experienced a significant block deal, where BC Investments IV Limited, a Mauritius-based investment entity and an affiliate of Bain Capital, divested 18 lakh shares valued at Rs 289 crore. The buyer, Norges Bank on behalf of The Government Pension Fund Global, acquired these shares at Rs 1,608.2 each. Following this transaction, Emcure’s stock closed with a robust gain of 8% at Rs 1,729.90 on the National Stock Exchange (NSE). This development underscores a notable interest in the pharmaceutical sector, particularly in companies with a solid performance background.
Emcure Pharmaceuticals has demonstrated remarkable growth, with a 67% return on its stock over the past year, particularly in contrast to the broader market benchmarks—the Nifty and BSE Sensex—which faced declines of 1% and 3%, respectively. As of March 31, 2026, BC Investments IV held a total of 73.39 lakh shares, accounting for a 3.87% stake in the company. The stock’s current trading prices are also above key technical indicators, with its 50-day and 200-day simple moving averages sitting at Rs 1,535 and Rs 1,438, respectively, indicating strong momentum in shareholder sentiment.
The company’s financial health appears robust, having reported a consolidated net profit of Rs 231 crore, marking a significant 50% increase from Rs 154 crore in the same quarter of the previous year. Additionally, total revenue rose by 20% year-over-year to Rs 2,365 crore, up from Rs 1,966 crore in the corresponding period. As a small-cap stock with a market capitalization of Rs 32,742 crore, Emcure maintains a strong position in the pharmaceutical market, specializing in manufacturing active pharmaceutical ingredients (APIs) and formulations. This financial performance bodes well for future growth prospects and investor interests in the company.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova team.)